NCT04934540Recruiting
The Global En Bloc Resection of Bladder Tumour Registry
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The study aims to collect data on ERBT globally in order to clarify its role in the management of bladder cancer over a 5-year observation period.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 11 Nov 2020
- Start date
- 1 Jan 2020
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Bladder cancer
- NCT number
- NCT04934540
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Jan 2020 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence or previous history of upper tract urothelial carcinoma
Other illness
- Presence of other active malignancy
Other
- Pregnancy
Who the study is looking for
- Adult patients \>=18 years old with informed consent
- Presence of bladder tumour undergoing transurethral ERBT
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
| North District Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.